Cancer/testis antigen 1 (86-97)

Cancer/testis antigen 1 (86-97) is a synthetic peptide fragment derived from the well-characterized cancer/testis antigen 1 (CTAG1), also known as NY-ESO-1. This peptide corresponds to amino acids 86 through 97 of the full-length antigen and represents a region frequently recognized by the immune system in various malignancies. Due to its restricted expression pattern—being predominantly found in germ cells of the testis and aberrantly expressed in multiple tumor types—this peptide has emerged as a valuable tool in immunological research, tumor antigen discovery, and studies focused on antigen processing and presentation. Its defined amino acid sequence and immunogenic properties make it especially relevant for applications in basic cancer immunology, peptide-based assay development, and T cell epitope mapping.

Epitope mapping: Researchers utilize the 86-97 fragment of CTAG1 in precise mapping of T cell epitopes associated with tumor antigens. By incorporating this peptide into in vitro assays, scientists can identify and characterize the specific CD8+ or CD4+ T cell responses elicited by this region of the antigen. Such studies are instrumental in delineating the immunodominant regions of cancer/testis antigens, advancing the understanding of tumor immune recognition, and supporting the rational design of immunotherapeutic strategies.

Immunogenicity assessment: The peptide serves as a model antigen for evaluating the immunogenic potential of cancer/testis antigens in various experimental systems. Its use in ELISPOT, intracellular cytokine staining, or proliferation assays enables quantification and functional analysis of antigen-specific T cells in patient-derived samples or experimental animal models. These assessments are critical for gauging the breadth and specificity of immune responses to tumor-associated antigens and for optimizing antigen selection in preclinical research.

Peptide-MHC binding studies: The defined sequence of the 86-97 peptide allows for detailed investigation of peptide-MHC (major histocompatibility complex) interactions. By studying its binding affinity and stability with different HLA alleles, researchers can elucidate the molecular determinants that govern antigen presentation and T cell recognition. Such insights are valuable for predicting population coverage of immune responses and for the rational development of peptide-based immunotherapies or vaccines.

Synthetic peptide controls: In immunological assays, this peptide is frequently employed as a positive control or standard for assay validation. Its well-characterized immunogenicity and reproducible reactivity make it suitable for benchmarking assay sensitivity, specificity, and reproducibility. Use as a control peptide ensures the reliability of experimental results and facilitates the standardization of immune monitoring protocols across laboratories and studies.

Antigen processing research: The Cancer/testis antigen 1 (86-97) peptide is instrumental in dissecting the pathways of antigen processing and presentation in tumor cells and antigen-presenting cells. By tracking peptide generation, loading onto MHC molecules, and subsequent T cell activation, scientists can investigate the efficiency and fidelity of antigen presentation machinery. These studies provide foundational insights into immune evasion mechanisms in cancer and inform strategies to enhance the visibility of tumor antigens to the immune system.

1. Zeta-potential-changing nanoparticles conjugated with cell-penetrating peptides for enhanced transfection efficiency

2. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes

3. Implications of ligand-receptor binding kinetics on GLP-1R signalling

4. Exosomes-mediated Transfer of miR-125a/b in Cell-to-cell Communication: A Novel Mechanism of Genetic Exchange in the Intestinal Microenvironment

5. High fat diet and GLP-1 drugs induce pancreatic injury in mice